Description
IGF-BP3 is a 30 kDa, cysteine-rich secreted protein. It is the major IGF binding protein present in the plasma of human and animals, and it is also found in α-granules of platelets. In addition to its ability to modulate the activity of IGF-I and IGF-II, IGF-BP3 exerts inhibitory effects on follicle stimulating hormone (FSH) activity. Decreased plasma levels of IGF-BP3 often results in dwarfism, whereas elevated levels of IGF-BP3 may lead to acromegaly. The expression of IGF-BP3 in fibroblasts is stimulated by mitogenic growth factors, such as Bombesin, Vasopressin, PDGF, and EGF. Recombinant Human IGF-BP3 is a 28.8 kDa protein consisting of 264 amino acid residues.
Product Properties
|
Synonyms
|
Growth-hormone-dependant Binding Protein, IBP-3, IGF-binding protein 3
|
|
Accession
|
P17936
|
|
GeneID
|
3486
|
|
Source
|
E.coli-derived Human IGF-BP3 protein,Gly28-Lys291
|
|
Molecular Weight
|
Approximately 28.8 kDa.
|
|
AA Sequence
|
GASSAGLGPV VRCEPCDARA LAQCAPPPAV CAELVREPGC GCCLTCALSE GQPCGIYTER CGSGLRCQPS PDEARPLQAL LDGRGLCVNA SAVSRLRAYL LPAPPAPGNA SESEEDRSAG SVESPSVSST HRVSDPKFHP LHSKIIIIKK GHAKDSQRYK VDYESQSTDT QNFSSESKRE TEYGPCRREM EDTLNHLKFL NVLSPRGVHI PNCDKKGFYK KKQCRPSKGR KRGFCWCVDK YGQPLPGYTT KGKEDVHCYS MQSK
|
|
Tag
|
None
|
|
Physical Appearance
|
Sterile Filtered White lyophilized (freeze-dried) powder.
|
|
Purity
|
> 98 % by SDS-PAGE and HPLC analyses.
|
|
Biological Activity
|
Fully biologically active when compared to standard. The ED50 as determined by inhibiting IGF-II induced proliferation of serum free human MCF-7 cells is less than 200 ng/mL, corresponding to a specific activity of > 5.0 × 103 IU/mg in the presence of 15 ng/mL of rHuIGF-II.
|
|
Endotoxin
|
< 1 EU per 1μg of the protein by the LAL method.
|
|
Formulation
|
Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.
|
|
Reconstitution
|
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.
|
Shipping and Storage
The products are shipped with ice pack and can be stored at -20℃ to -80℃ for 1 year.
Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.
Cautions
1. Avoid repeated freeze-thaw cycles.
2. For your safety and health, please wear lab coats and disposable gloves for operation.
3. For research use only!
